Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557265 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
A Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy, sponsored by Nkarta.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 16
- Study locations
NCT06557265: Recruiting Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy, sponsored by Nkarta.
NCT06557265 is a Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy that is actively recruiting participants, run by Nkarta. The registered enrollment target is 96 participants, below the 307-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (69% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06557265, a Phase 1 study of Lupus Nephritis and Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Nkarta.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).
Primary Outcome
Incidence of DLTs will be evaluated
Conditions Studied
Interventions
- DRUG NKX019
- DRUG Fludarabine, Cyclophosphamide
Study Locations (16)
Florida
- Nkarta Investigational Site - Gainesville
- Nkarta Investigational Site - Miami
- Nkarta Investigational Site - Plantation
- Nkarta Investigational Site - Tampa
New York
- Nkarta Investigational Site - New York
- Nkarta Investigational Site - Stony Brook
- Nkarta Investigational Site - Syracuse
Texas
- Nkarta Investigational Site - Dallas
- Nkarta Investigational Site - Houston
Arkansas
- Nkarta Investigational Site - Little Rock
Georgia
- Nkarta Investigational Site - Atlanta
Illinois
- Nkarta Investigational Site - Chicago
Louisiana
- Nkarta Investigational Site - New Orleans
Massachusetts
- Nkarta Investigational Site - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT06557265 shows while recruiting
NCT06557265 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 307-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions - of which NKX019 is the first listed.
NCT06557265 lists 16 locations in 10 states (Florida, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT06557265 about?
NCT06557265 is a clinical study titled "A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)". This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy (pMN).
What is the current status of trial NCT06557265?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-06-13. Estimated completion is 2027-04.
What conditions does trial NCT06557265 study?
This clinical trial studies the following conditions: Lupus Nephritis, Primary Membranous Nephropathy.
What interventions are being tested in trial NCT06557265?
The interventions under investigation include: NKX019 (DRUG), Fludarabine, Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT06557265?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06557265 being conducted?
This trial has 16 study locations across Arkansas, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06557265's enrollment target sits among peer trials
96 14th of 30 higher than 17 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI